ELVN

Enliven Therapeutics (ELVN)

About Enliven Therapeutics (ELVN)

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Details

Daily high

$31.32

Daily low

$29.37

Price at open

52 Week High

$31.76

52 Week Low

$13.30

Market cap

1.8B

Dividend yield

0.00%

Volume

311

Avg. volume

1.0M

P/E ratio

-16.58

Enliven Therapeutics News